An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' COPD Vaccine (GSK3277511A) in Adults
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs GSK 3277511 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics
- Acronyms NTHI MCAT-008
- Sponsors GlaxoSmithKline Biologicals
- 31 May 2018 Status changed from recruiting to active, no longer recruiting.
- 08 May 2018 Planned End Date changed from 7 Nov 2019 to 5 May 2020.
- 08 May 2018 Planned primary completion date changed from 7 Nov 2019 to 5 May 2020.